← Eichor
Condition: Gene Rearrangement Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Gene Rearrangement

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Phase 2 · 44 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT05678270A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07101497Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01371630Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Pres
Phase 2 · 27 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT06620835Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Ly
Phase 2 · 2 location(s) · University of California, Davis · NCT05600686BY002 IIT Study in R/R Acute Leukemia
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07270770A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT
Phase N/A · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07559695SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Phase 1 · 1 location(s) · Guangzhou JOYO Pharma Co., Ltd · NCT06128148Mutational Oncology in Clinical Practice
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06020625Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Le
Phase 2 · 4 location(s) · Mayo Clinic · NCT03418038Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Ly
Phase N/A · 20 location(s) · Fondazione Italiana Linfomi - ETS · NCT06588205Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Phase 1 · 4 location(s) · Tyra Biosciences, Inc · NCT06160752Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
Phase 2 · 20 location(s) · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · NCT06552234A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leuke
Phase 3 · 253 location(s) · Janssen Research & Development, LLC · NCT06852222Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT04432714Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Phase 2 · 65 location(s) · Taiho Oncology, Inc. · NCT05727176Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Phase 1 · 1 location(s) · Lapo Alinari · NCT05755087The Contribution of Optical Mapping to the Characterization of Chromosomal Rearrangements in Patients With Neurodevelopm
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07133789A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcita
Phase 2 · 53 location(s) · Hoffmann-La Roche · NCT06806033Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Phase 1/Phase 2 · 8 location(s) · National Cancer Institute (NCI) · NCT07069699Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R)
Phase 2 · 1 location(s) · University of Washington · NCT07097363Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Yazeed Sawalha · NCT06536049Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Expo
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07042438Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NA · 46 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT05122806A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Phase 2 · 19 location(s) · Elevar Therapeutics · NCT07359820
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.